Federal regulators have cleared a new technological tool designed to help clinicians identify children with autism, marking another step forward in the integration of artificial intelligence and biometrics into pediatric healthcare.
The Food and Drug Administration cleared the tool, known as Neurora, this month to inform clinical decisions regarding the diagnosis of children ranging from 18 months to 12 years old. Developed by Argus Cognitive, Inc., the software system uses more than 100 distinct biometrics to assess whether a child displays behavioral patterns consistent with autism spectrum disorder.
The clearance arrives as the medical and developmental disability communities continue to grapple with high demand for evaluations, long waiting lists, and a median age of diagnosis that remains just under 4 years old, according to the Centers for Disease Control and Prevention. Federal data underscores the urgency of these challenges, with recent CDC estimates indicating that autism now affects approximately 1 in 31 children nationwide.
Under the operational framework established by Argus Cognitive, clinicians utilize the Neurora portal by uploading video and audio recordings obtained during standard behavioral assessments. The system then processes these recordings, measuring facial expressions, voice patterns, eye gaze, and other fine-grained behavioral markers. Through this automated analysis, the tool evaluates how a child’s specific behaviors compare against established datasets of children both with and without autism.
Company officials emphasize that the software is not intended to replace human expertise or serve as a standalone diagnostic instrument. Instead, the resulting data is designed to be considered in conjunction with other clinical findings and professional judgment.
"We built Neurora to support clinicians evaluating children for autism," said Dr. Attila Meretei, CEO and co-founder of Argus Cognitive. "Neurora works inside the assessment clinicians already use, without protocol changes or proprietary hardware, and is fully automated. Our goal is to reinforce every diagnosis with robust, quantitative evidence."
The development of Neurora reflects a growing trend toward technology-assisted evaluations in developmental pediatrics, supported in part by public funding mechanisms aimed at healthcare innovation. Argus Cognitive noted that the creation and refinement of the tool were supported by a National Institutes of Health grant geared toward entrepreneurs and early-stage medical technology.
Scientific backing for the tool was published earlier this year in a study detailing its efficacy. According to the research findings, the biometric system successfully distinguished between children with and without autism in nearly 78 percent of cases, providing a quantifiable layer of supportive evidence for evaluating physicians and specialists.
With this latest regulatory clearance, Neurora joins a small but growing roster of FDA-cleared devices available to diagnosticians aiming to streamline and objectify the evaluation process for young children. In recent years, federal regulators have cleared a few other specialized diagnostic tools that approach the challenge from different technological angles.
For instance, the FDA previously cleared the EarliPoint Evaluation for ASD, which relies on specialized eye-tracking technology to analyze a child’s visual behavior in real time during social interactions. Additionally, regulators previously cleared Canvas Dx, an algorithm-driven software system that analyzes parental questionnaires, information submitted by healthcare providers, and video submissions of the child to help guide clinical decision-making regarding potential diagnoses.
Despite these technological advancements, healthcare systems continue to face systemic hurdles. Families across the United States frequently report waiting months—and sometimes over a year—to secure appointments with developmental pediatricians, child psychologists, or specialized autism diagnostic centers. Experts hope that tools capable of assisting primary care providers and speeding up the initial evaluation phase can help alleviate bottlenecks in the healthcare system, enabling children to access critical early intervention services at a younger age.
As Argus Cognitive prepares to introduce Neurora to clinical practices, the broader medical community continues to weigh the benefits and practical applications of biometric and AI-driven diagnostic aids. While the ultimate responsibility for an autism diagnosis remains firmly in the hands of trained medical professionals, innovations like Neurora signal a shift toward data-backed clinical support designed to bring greater consistency, confidence, and objectivity to the evaluation process for families navigating the developmental disability system.
